OncoPharm

Follow OncoPharm
Share on
Copy link to clipboard

Oncology Pharmacist & Educator. Talking all things #oncopharm

John Bossaer


    • May 29, 2025 LATEST EPISODE
    • weekly NEW EPISODES
    • 17m AVG DURATION
    • 381 EPISODES

    4.9 from 159 ratings Listeners of OncoPharm that love the show mention: pharmacists, keep up to date, drugs, hospital, clinical, concise, john, excellent podcast, outstanding, resource, helpful, music, information, highly, host, thank, good, recommend, informative, new.


    Ivy Insights

    The OncoPharm podcast is a fantastic resource for anyone interested in oncology. Whether you're a student, resident, pharmacist, or healthcare professional, this podcast offers valuable insights and updates in the field of oncology. The host does a great job of reviewing new drugs and treatments, as well as providing in-depth discussions on old treatment regimens. The format and style of the podcast are engaging and informative, making it easy to absorb the information being presented.

    One of the best aspects of The OncoPharm podcast is its ability to provide updates on new and emerging therapies in oncology. The host keeps listeners up to date with the latest developments in the field and discusses their potential impact on patient care. This is particularly helpful for healthcare professionals who need to stay informed about advancements in oncology treatment options.

    Another great aspect of this podcast is the "foundations series" where the host dives deep into specific topics and provides thorough explanations that are easy to understand. This is especially beneficial for students or those new to oncology who may need a more comprehensive overview of certain concepts or treatments.

    However, one potential downside of this podcast is that it may not be organized by topic for easy access to old episodes. This can make it difficult for listeners to find specific information they are looking for, especially if they want to revisit an episode on a particular topic.

    In conclusion, The OncoPharm podcast is an excellent resource for anyone interested in oncology. It offers informative discussions on new drugs and treatments while also providing a comprehensive understanding of existing therapies. While there may be room for improvement in terms of organization, the overall content and format make this podcast highly recommended for anyone wanting to stay up to date with developments in oncology.



    Search for episodes from OncoPharm with a specific topic:

    Latest episodes from OncoPharm

    CLEOPATRA

    Play Episode Listen Later May 29, 2025 11:17


    Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.

    Talking about cancer misinformation

    Play Episode Listen Later May 22, 2025 15:27


    If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you. 1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857 2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526

    Four New Drugs

    Play Episode Listen Later May 22, 2025 12:20


    Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.

    Mg to Prevent Cisplatin Kidney Injury

    Play Episode Listen Later May 8, 2025 15:48


    A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury. Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756 PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351 Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/

    TI-CH, Updates on dostarlimab, ventoclax, & zongertinib

    Play Episode Listen Later May 1, 2025 12:11


    This episode summarizes recent updates on: Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)

    tumors dostarlimab
    BRCA Reversion Mutations

    Play Episode Listen Later Apr 24, 2025 12:43


    BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors. Bibliography: 1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715 2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933 3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015

    HOPA 25 Recap

    Play Episode Listen Later Apr 17, 2025 11:45


    Recapping HOPA 25 and Portland *Great food (not discussed, the most excellent ETSU dinner at Arden) *COCOON *Pharmacists make everyone's job easier and keep patients out of the ED *A few more tidbits too!

    Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview

    Play Episode Listen Later Apr 8, 2025 12:25


    FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.

    Topotecan

    Play Episode Listen Later Apr 3, 2025 9:46


    A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)

    foundations topotecan
    API-CAT & IMPROVE

    Play Episode Listen Later Apr 3, 2025 12:42


    We discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)

    Keynote 811 Update

    Play Episode Listen Later Mar 19, 2025 12:59


    The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.

    Polar: Cryotherapy or Compression to Prevent Taxane-induced neuropathy

    Play Episode Listen Later Mar 13, 2025 9:59


    There is a decent track record with mixed results for cryotherapy to prevent taxane-induced peripheral neuropathy. The POLAR trial adds to this body of evidence that trends in favor of cryotherapy. Compression therapy is another alternative. Both are studied in POLAR. POLAR: doi:10.1001/jamaoncol.2025.0001

    About Herb Drug Interactions

    Play Episode Listen Later Mar 6, 2025 11:48


    Ten of the top herb-chemotherapy interactions. About Herbs website: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/search Also, search 'About Herbs' in your app store.

    Rethinking Premeds

    Play Episode Listen Later Feb 27, 2025 8:35


    Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time! Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158 Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470 We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.

    AMPLIFY

    Play Episode Listen Later Feb 20, 2025 17:25


    We take a deep look at the recently published, and guideline changing, AMPLIFY trial of fixed-duration acalabrutinib in CLL. Link: DOI: 10.1056/NEJMoa2409804

    OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma post-CAR-T

    Play Episode Listen Later Feb 13, 2025 12:35


    Morbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports. 1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-fatal-tumor-lysis-syndrome-in-a-patient-with-acute-myeloid-leukemia-receiving-azacitidine-and-venetoclax-without-a-ramp-up-schedule-a-case-report 2. CD4+ T-cell lymphoma harboring a CAR integration into TP53: https://www.nejm.org/doi/full/10.1056/NEJMoa2411507

    [Re-release] Rituximab

    Play Episode Listen Later Feb 6, 2025 18:34


    Dipping into the archives (technology issues with new computer) to re-release the Foundations of OncoPharm episode on rituximab. Where did that 375 mg/m2 dose come from anyway?

    Acalabrutinb + BR and sotorasib + panitumumab

    Play Episode Listen Later Jan 30, 2025 8:47


    FDA approves two new treatment regimens: 1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

    Datoptamab deruxtecan

    Play Episode Listen Later Jan 22, 2025 18:49


    Datopotamab deruxtecan, a newly approved agent for breast cancer, is discussed.

    Dex Dosing in MM, Tec-Tal, & postMONARCH

    Play Episode Listen Later Jan 16, 2025 12:17


    HOPA Pharmacy Outcomes & Practice-Based Collaboration Survey: https://www.surveymonkey.com/r/MXNVRBR Dexamethasone Dosing Intensity in Multiple Myeloma: https://doi.org/10.1182/blood.2024025939 Talquetamab + Teclistamab: https://doi.org/10.1182/blood.2024025939 postMONARCH: https://doi.org/10.1200/JCO-24-02086

    Breakwater, Ensartinib, & SC Nivo

    Play Episode Listen Later Jan 9, 2025 10:52


    We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

    The Accelerated Approval Pathway

    Play Episode Listen Later Jan 2, 2025 13:14


    Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer. Article: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Forest R, et al. Lancet Oncology 2024. Link: https://doi.org/10.1016/S1470-2045(24)00596-5

    2024 New Drug Review

    Play Episode Listen Later Dec 19, 2024 18:03


    Looking back at new approvals from 2024 - what to keep, re-gift, or return? And yes, as soon as this was recorded 2 new drugs were approved.

    A Feast Of Updates

    Play Episode Listen Later Dec 12, 2024 17:05


    Lots of recent clinical trial updates to discuss: AQUILA: Daratumumab for high-risk smoldering multiple myeloma Checkmate 8HW: Nivo/Ipi for MSI-high/MMRd metastatic colorectal cancer DESTINY-Breast06: T-DXd in HER2-low MBC after hormonal treatment, but without previous chemo for MBC ARMANI: Switch maintenance ramucirumab-paclitaxel in metastatic gastric/GEJ cancer HELEN-006: Neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab vs. TCHP in breast cancer SONIA: finally published!

    Zenocutuzumab

    Play Episode Listen Later Dec 5, 2024 12:45


    A first-in-class approval of a bispecific HER2-HER3 monoclonal antibody for NRG1 fusion (+) NSCLC and pancreatic cancer.

    Revumenib

    Play Episode Listen Later Nov 21, 2024 14:52


    The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias. Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265

    Anthracycline Use In Breast Cancer

    Play Episode Listen Later Nov 14, 2024 9:52


    A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-01916 10-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836 Bonus - Practical Guide for Testing for Pharmacogenomics: https://doi.org/10.1200/OP.24.00191

    SWISH

    Play Episode Listen Later Nov 7, 2024 9:18


    Reviewing the data to support use of dexamethasone solution mouthwash for PIK3/AKT/mTOR inhibitor-induced stomatitis, caused by drugs like everolimus, alpelisib, capivasertib, & inavolisib. SWISH: https://doi.org/10.1016/s1470-2045(17)30109-2 Alliance MIST Trial: https://doi.org/10.1053/j.seminoncol.2023.01.001

    Zolbetuximab

    Play Episode Listen Later Oct 31, 2024 19:30


    The first Cldn 18.2 targeting monoclonal antibody has been improved. Let's talk about it!

    S1826 & INTERLACE

    Play Episode Listen Later Oct 24, 2024 22:49


    Discussing two excellent articles from earlier this month. S1826: N-AVD vs. Bv-AVD (DOI: 10.1056/NEJMoa2405888) & INTERLACE: induction chemo prior to concurrent cisplatin/RT in locally advanced cervical cancer (DOI: https://doi.org/10.1016/S0140-6736(24)01438-7)

    Inavolisib

    Play Episode Listen Later Oct 17, 2024 16:42


    A new PIK3Ca inhibitor is approved for breast cancer.

    Autumnal (2024) AML Updates

    Play Episode Listen Later Oct 10, 2024 13:48


    Reviewing 3 recent AML publications Double-Dauno (90 mg/m2 vs. 60 mg/m2): https://doi.org/10.1200/JCO.24.00235 AML60+ Risk Stratification: https://doi.org/10.1200/JCO.23.02631 Decitabine-Ven as bridge to Allo HSCT: https://doi.org/10.1016/S2352-3026(24)00241-2

    MSI-High Rectal Cancer Treatment

    Play Episode Listen Later Oct 3, 2024 10:03


    MSI-high/MMRd rectal cancer treatment guidelines are being re-written. A brief synopsis of why treatment guidelines are changing so quickly in this space. Also, listeners helped out in explaining the ribociclib storage & stability change. Hint: https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2

    NATALEE + a slew of FDA updates

    Play Episode Listen Later Sep 26, 2024 16:39


    FDA has been busy the last week approving: -ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement -osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC -amivantamab + chemotherapy following progression on osimertinib (Mariposa-2) -a subcutaneous formulation of atezolizumab -isatuximab + VRD for multiple myeloma -pembrolizumab + chemotherapy for metastatic pleural mesothelioma

    ESMO 2024

    Play Episode Listen Later Sep 19, 2024 22:17


    Recapping just some of the notable data coming out of ESMO 2024: -Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC) -AMBASSADOR (adjuvant pembrolizumab in bladder cancer) -NIAGRA (perioperative durvalumab in bladder cancer) -ADRIATIC (discussed on ASCO recap Pod, but publication now available) -LEANOX (impact of lean body mass adjustment on oxaliplatin dose)

    Doxorubicin + Trabectedin

    Play Episode Listen Later Sep 5, 2024 17:00


    LMS04 final OS results are published for doxorubicin + trabectedin in Leiomyosarcoma. Plus, a natural experiment of what happens in small cell lung cancer during an IV etoposide shortage. Finally, a nice paper provides some examples of how oncology pharmacists can bridge the care gap between oncology and primary care. LMS04: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2403394 IV etoposide shortage: https://doi.org/10.1200/OP.24.00394 Primary care - oncology pharmacy collaboration: https://doi.org/10.1177/10781552241279303

    os iv doxorubicin leiomyosarcoma
    Chapter 1. Doses Matter

    Play Episode Listen Later Aug 29, 2024 22:48


    This is chapter 1 of a keynote address from summer 2024 on putting together the pieces of oncology pharmacy - with an emphasis on how our knowledge of drug dosing changes with time. Video/slides available at YouTube: https://youtu.be/1Oae8AV5Af4

    Cross-Trial Comparison Don'ts

    Play Episode Listen Later Aug 22, 2024 19:31


    We all know we aren't supposed to make cross-trial comparisons, but it happens anyway. So, let's compare FLARUA2 (osimertinb + chemo) and the newly FDA-approved MARIPOSA regimen (lazertinib + amivantamab) to see what we can (and can't) take away from such a dangerous cross-trial comparison.

    Olanzapine For MEC

    Play Episode Listen Later Aug 15, 2024 14:17


    A mixed bag of Phase III results for using olanzapine with moderately emegotenic chemotherapy (MEC). Inui, et al: https://doi.org/10.1200/JCO.24.00278 Ostwal, et al: doi:10.1001/jamanetworkopen.2024.26076

    Afamitresgene Autoleucel & Vorasidenib

    Play Episode Listen Later Aug 8, 2024 12:29


    A new cellular therapy is approved for synovial sarcoma and the anticipated approval has occurred for the dual IDH1/IDH2 inhibitor, vorasidenib.

    Perioperative ICI Trial Design & Blood Test Screening For Colorectal Cancer

    Play Episode Listen Later Jul 31, 2024 15:47


    FDA appears to change its stance on evaluating perioperative (adjuvant followed by neoadjuvant) ICI study designs in NSCLC. Also, a simple blood test is approved to detect colorectal cancer, but there are several limitations compared to colonoscopy.

    The Auto Transplant Breast Cancer Scandal

    Play Episode Listen Later Jul 25, 2024 15:28


    Did you know high-dose chemotherapy with autologous stem cel rescue was a "standard" breast cancer treatment ~30 years ago? This story involves changing practices based on Phase II data and outright clinical trial fraud, and retractions of publications. On-site review of Bezwoda study: https://doi.org/10.1016/S0140-6736(00)90024-2 Oral History: https://cancerhistoryproject.com/institutions/nccns-bob-carlson-talks-about-the-day-he-stormed-out-of-a-meeting-with-transplanters/

    Vacation Reflections

    Play Episode Listen Later Jul 18, 2024 9:24


    Reflections from vacation on 1) How similar the chef training experience on The Bear mirrors some pharmacy residency training and 2) being a resource to family/friends with oncology questions.

    June '24 Updates & ATOPP Travelogue

    Play Episode Listen Later Jul 3, 2024 14:19


    Running through recent updates on epcoritamab, adagrasib + cetuximab for colorectal cancer, endometrial cancer, adjuvant dabrafenib/trametinib melanoma follow-up data, and topical capsaicin for delayed CINV. Also, a brief travelogue on my inaugural trip to ATOPP (advanced topics for oncology pharmacy professionals) Summit.

    MARIPOSA

    Play Episode Listen Later Jun 27, 2024 10:20


    The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.

    ViPOR

    Play Episode Listen Later Jun 21, 2024 13:38


    An experimental regimen for DLBCL piques my interest. Venetoclax ibrutinib Prednisone Obinutuzumab Revlimid (lenalidomide) Link: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401532

    Imetelstat, Targeting Telomerase

    Play Episode Listen Later Jun 13, 2024 12:11


    A new drug is approved for MDS. While some will likely benefit from this new agent, the more enticing news is that inhibiting telomerase may be an attractive target for many malignancies.

    ASCO 2024

    Play Episode Listen Later Jun 6, 2024 25:08


    Lots and lots of updates from the past weekend's ASCO annual meeting. 1. ADRIATIC (consolidation durvalumab in limited stage SCLC) 2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma) 3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer) 4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer) 5. TRANSMET (liver transplantation in colon cancer with liver mets) 6. Eposec (FLOT > CROSS in adenocarcinoma of the esophagus) 7. LAURA (forever osimertinib in stage III EGFR-mutated NSCLC post-chemoRT) 8. CROWN (5 year update of lorlatinib in ALK+ NSCLC) 9. Destiny Breast-06 (T-DXd vs. chemo in HER-2 low and "ultra" low MBC who haven't received chemo in metastatic setting) 10. ASC4FIRST (Asciminib first line in CML. Funny title, amirite?)

    Updated ASCO-ONS Antineoplastic Safety Standards

    Play Episode Listen Later May 30, 2024 13:16


    ASCO & ONS (along with pharmacist representation) released updated safety standards for preparing, administering, and monitoring chemotherapy. Look for a calendar invitation to review your site's policies soon. Link: https://doi.org/10.1200/OP.24.00216

    Tarlatamab

    Play Episode Listen Later May 23, 2024 10:12


    A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.

    QT Prolongation In Oncology

    Play Episode Listen Later May 16, 2024 14:56


    QT interval prolongation is a common hurdle to taking care of cancer patients. We dive into what QT interval prolongation is, why it matters, risk factors, and prevention/management strategies.

    Claim OncoPharm

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel